138 related articles for article (PubMed ID: 36215568)
21.
Pathmanandavel S; Crumbaker M; Yam AO; Nguyen A; Rofe C; Hovey E; Gedye C; Kwan EM; Hauser C; Azad AA; Eu P; Martin AJ; Joshua AM; Emmett L
J Nucl Med; 2022 Apr; 63(4):560-566. PubMed ID: 34326127
[No Abstract] [Full Text] [Related]
22. Clinical Experience with [
Alan-Selcuk N; Beydagi G; Demirci E; Ocak M; Celik S; Oven BB; Toklu T; Karaaslan I; Akcay K; Sonmez O; Kabasakal L
J Nucl Med; 2023 Oct; 64(10):1574-1580. PubMed ID: 37620050
[TBL] [Abstract][Full Text] [Related]
23. Early molecular imaging response assessment based on determination of total viable tumor burden in [
Rosar F; Wenner F; Khreish F; Dewes S; Wagenpfeil G; Hoffmann MA; Schreckenberger M; Bartholomä M; Ezziddin S
Eur J Nucl Med Mol Imaging; 2022 Apr; 49(5):1584-1594. PubMed ID: 34725725
[TBL] [Abstract][Full Text] [Related]
24. Dual-Time-Point Posttherapy
Straub M; Kupferschläger J; Serna Higuita LM; Weissinger M; Dittmann H; la Fougère C; Fiz F
J Nucl Med; 2023 Sep; 64(9):1431-1438. PubMed ID: 37414446
[No Abstract] [Full Text] [Related]
25. Prognostic importance of prostatic specific antigen response in patients who received Lutetium-177 prostate-specific membrane antigen treatment for castration resistant prostate cancer.
Soydal C; Araz M; Urun Y; Nak D; Ozkan E; Kucuk NO
Q J Nucl Med Mol Imaging; 2021 Sep; 65(3):282-286. PubMed ID: 31602963
[TBL] [Abstract][Full Text] [Related]
26. Real-world Outcomes and Predictive Biomarkers for
Kafka M; Horninger A; di Santo G; Virgolini I; Neuwirt H; Unterrainer LM; Kunte SC; Deiss E; Paffenholz P; Heidenreich A; Rasul S; Einspieler H; Shariat SF; Rajwa P; Dozauer R; Tsaur I; Medlock E; Rölz N; Rausch S; la Fougère C; Trautwein N; Roesch MC; Merseburger AS; Zattoni F; Sepulcri M; Ladurner M; Bektic J; Gandaglia G; Horninger W; Heidegger I
Eur Urol Oncol; 2024 Jun; 7(3):421-429. PubMed ID: 37604763
[TBL] [Abstract][Full Text] [Related]
27. Molecular analysis of circulating tumor cells of metastatic castration-resistant Prostate Cancer Patients receiving
Kessel K; Seifert R; Weckesser M; Roll W; Humberg V; Schlack K; Bögemann M; Bernemann C; Rahbar K
Theranostics; 2020; 10(17):7645-7655. PubMed ID: 32685010
[No Abstract] [Full Text] [Related]
28. PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [
Buteau JP; Martin AJ; Emmett L; Iravani A; Sandhu S; Joshua AM; Francis RJ; Zhang AY; Scott AM; Lee ST; Azad AA; McJannett MM; Stockler MR; Williams SG; Davis ID; Hofman MS;
Lancet Oncol; 2022 Nov; 23(11):1389-1397. PubMed ID: 36261050
[TBL] [Abstract][Full Text] [Related]
29. mCRPC Patients Receiving
Sathekge M; Bruchertseifer F; Vorster M; Lawal IO; Knoesen O; Mahapane J; Davis C; Mdlophane A; Maes A; Mokoala K; Mathabe K; Van C; Wiele D; Morgenstern A
J Nucl Med; 2022 Oct; 63(10):1496-1502. PubMed ID: 35177427
[No Abstract] [Full Text] [Related]
30. Activity of Lutetium-177 Prostate-specific Membrane Antigen and Determinants of Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Cabazitaxel: The PACAP Study.
Flippot R; Telli T; Velev M; Fléchon A; De Vries-Brilland M; Turpin L; Bergman A; Turco F; Mahammedi H; Fendler WP; Giraudet AL; Josset Q; Montravers F; Vogel W; Gillessen S; Berardi Vilei S; Herrmann K; Kryza D; Paone G; Hadaschik B; Merlin C; Dufour PA; Bernard-Tessier A; Naoun N; Patrikidou A; Garcia C; Foulon S; Pagès A; Fizazi K
Eur Urol Oncol; 2024 Apr; ():. PubMed ID: 38664139
[TBL] [Abstract][Full Text] [Related]
31. TheraP: a randomized phase 2 trial of
Hofman MS; Emmett L; Violet J; Y Zhang A; Lawrence NJ; Stockler M; Francis RJ; Iravani A; Williams S; Azad A; Martin A; McJannett M; ; Davis ID
BJU Int; 2019 Nov; 124 Suppl 1():5-13. PubMed ID: 31638341
[TBL] [Abstract][Full Text] [Related]
32. The
Maffey-Steffan J; Scarpa L; Svirydenka A; Nilica B; Mair C; Buxbaum S; Bektic J; von Guggenberg E; Uprimny C; Horninger W; Virgolini I
Eur J Nucl Med Mol Imaging; 2020 Mar; 47(3):695-712. PubMed ID: 31776632
[TBL] [Abstract][Full Text] [Related]
33. Nomograms to predict outcomes after
Gafita A; Calais J; Grogan TR; Hadaschik B; Wang H; Weber M; Sandhu S; Kratochwil C; Esfandiari R; Tauber R; Zeldin A; Rathke H; Armstrong WR; Robertson A; Thin P; D'Alessandria C; Rettig MB; Delpassand ES; Haberkorn U; Elashoff D; Herrmann K; Czernin J; Hofman MS; Fendler WP; Eiber M
Lancet Oncol; 2021 Aug; 22(8):1115-1125. PubMed ID: 34246328
[TBL] [Abstract][Full Text] [Related]
34. Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of
Violet J; Sandhu S; Iravani A; Ferdinandus J; Thang SP; Kong G; Kumar AR; Akhurst T; Pattison DA; Beaulieu A; Mooi J; Tran B; Guo C; Kalff V; Murphy DG; Jackson P; Eu P; Scalzo M; Williams S; Hicks RJ; Hofman MS
J Nucl Med; 2020 Jun; 61(6):857-865. PubMed ID: 31732676
[No Abstract] [Full Text] [Related]
35. Lutetium-177-PSMA-617 radioligand therapy in patients with high volume metastatic prostate cancer prior to chemotherapy and new generation androgen deprivation therapy: Clinical Experience.
Celen YZ; Elboga U; Sahin E; Kus T; Okuyan M; Cayirli YB; Erturhan S; Cimen U
Hell J Nucl Med; 2023; 26(3):187-193. PubMed ID: 38085834
[TBL] [Abstract][Full Text] [Related]
36. Activity and Adverse Events of Actinium-225-PSMA-617 in Advanced Metastatic Castration-resistant Prostate Cancer After Failure of Lutetium-177-PSMA.
Feuerecker B; Tauber R; Knorr K; Heck M; Beheshti A; Seidl C; Bruchertseifer F; Pickhard A; Gafita A; Kratochwil C; Retz M; Gschwend JE; Weber WA; D'Alessandria C; Morgenstern A; Eiber M
Eur Urol; 2021 Mar; 79(3):343-350. PubMed ID: 33293081
[TBL] [Abstract][Full Text] [Related]
37. Imaging expression of prostate-specific membrane antigen and response to PSMA-targeted β-emitting radionuclide therapies in metastatic castration-resistant prostate cancer.
Vlachostergios PJ; Niaz MJ; Skafida M; Mosallaie SA; Thomas C; Christos PJ; Osborne JR; Molina AM; Nanus DM; Bander NH; Tagawa ST
Prostate; 2021 Apr; 81(5):279-285. PubMed ID: 33465252
[TBL] [Abstract][Full Text] [Related]
38. Early Prostate-Specific Antigen Changes and Clinical Outcome After
Gafita A; Heck MM; Rauscher I; Tauber R; Cala L; Franz C; D'Alessandria C; Retz M; Weber WA; Eiber M
J Nucl Med; 2020 Oct; 61(10):1476-1483. PubMed ID: 32111687
[TBL] [Abstract][Full Text] [Related]
39. Response Assessment and Prediction of Progression-Free Survival by
Khreish F; Wiessner M; Rosar F; Ghazal Z; Sabet A; Maus S; Linxweiler J; Bartholomä M; Ezziddin S
Biomolecules; 2021 Jul; 11(8):. PubMed ID: 34439768
[TBL] [Abstract][Full Text] [Related]
40. Prediction of Response to
Hohberg M; Reifegerst M; Drzezga A; Wild M; Schmidt M
J Nucl Med; 2023 Nov; 64(11):1758-1764. PubMed ID: 37652546
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
